| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 29 | 2025 | 448 | 6.490 |
Why?
|
| Papillomavirus Infections | 16 | 2025 | 142 | 5.830 |
Why?
|
| Uterine Cervical Neoplasms | 11 | 2025 | 131 | 5.540 |
Why?
|
| Papillomavirus Vaccines | 15 | 2022 | 114 | 4.210 |
Why?
|
| Prostatic Neoplasms | 14 | 2024 | 263 | 3.340 |
Why?
|
| Early Detection of Cancer | 9 | 2025 | 529 | 3.320 |
Why?
|
| HIV Infections | 24 | 2020 | 712 | 3.290 |
Why?
|
| California | 56 | 2025 | 2317 | 2.940 |
Why?
|
| Humans | 117 | 2025 | 17376 | 2.710 |
Why?
|
| Delivery of Health Care, Integrated | 9 | 2024 | 537 | 2.430 |
Why?
|
| Adult | 67 | 2025 | 7529 | 2.340 |
Why?
|
| Female | 80 | 2025 | 12444 | 2.320 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2020 | 26 | 2.250 |
Why?
|
| Male | 75 | 2025 | 9843 | 2.150 |
Why?
|
| Young Adult | 41 | 2025 | 2473 | 2.010 |
Why?
|
| Mass Screening | 5 | 2025 | 671 | 1.960 |
Why?
|
| Terminal Care | 6 | 2025 | 46 | 1.900 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 14 | 1.890 |
Why?
|
| Cancer Survivors | 6 | 2025 | 101 | 1.850 |
Why?
|
| Middle Aged | 48 | 2025 | 7885 | 1.710 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 58 | 1.690 |
Why?
|
| Risk Factors | 33 | 2025 | 3255 | 1.630 |
Why?
|
| Adolescent | 40 | 2025 | 3533 | 1.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 53 | 1.520 |
Why?
|
| Managed Care Programs | 8 | 2017 | 309 | 1.340 |
Why?
|
| DNA Methylation | 2 | 2024 | 44 | 1.280 |
Why?
|
| Biomarkers, Tumor | 7 | 2017 | 145 | 1.270 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 533 | 1.260 |
Why?
|
| Aged | 34 | 2025 | 6129 | 1.230 |
Why?
|
| Incidence | 19 | 2025 | 1266 | 1.200 |
Why?
|
| Retrospective Studies | 18 | 2025 | 2428 | 1.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 366 | 1.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2017 | 165 | 1.130 |
Why?
|
| Cohort Studies | 29 | 2025 | 2526 | 1.130 |
Why?
|
| Lymphoma, AIDS-Related | 4 | 2012 | 18 | 1.120 |
Why?
|
| Survivors | 4 | 2024 | 157 | 1.080 |
Why?
|
| Guideline Adherence | 2 | 2019 | 152 | 1.070 |
Why?
|
| Anti-HIV Agents | 6 | 2018 | 159 | 1.060 |
Why?
|
| Time-to-Treatment | 2 | 2024 | 18 | 0.990 |
Why?
|
| Anemia | 2 | 2016 | 32 | 0.990 |
Why?
|
| Advance Care Planning | 2 | 2023 | 21 | 0.960 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 205 | 0.960 |
Why?
|
| Vaccination | 8 | 2022 | 685 | 0.950 |
Why?
|
| Viral Load | 8 | 2014 | 135 | 0.940 |
Why?
|
| Child | 23 | 2025 | 2382 | 0.940 |
Why?
|
| Street Drugs | 3 | 2009 | 12 | 0.900 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 2 | 2014 | 2 | 0.900 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2017 | 63 | 0.890 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 52 | 0.870 |
Why?
|
| Neutropenia | 2 | 2014 | 2 | 0.860 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 270 | 0.820 |
Why?
|
| Prognosis | 10 | 2020 | 604 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 244 | 0.800 |
Why?
|
| Papillomaviridae | 4 | 2025 | 61 | 0.780 |
Why?
|
| Vaginal Smears | 5 | 2024 | 47 | 0.770 |
Why?
|
| Social Class | 5 | 2024 | 117 | 0.770 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 246 | 0.770 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 174 | 0.760 |
Why?
|
| Case-Control Studies | 14 | 2024 | 1100 | 0.760 |
Why?
|
| CD4 Lymphocyte Count | 12 | 2017 | 181 | 0.760 |
Why?
|
| Alcohol Drinking | 3 | 2011 | 355 | 0.750 |
Why?
|
| Continental Population Groups | 3 | 2020 | 289 | 0.740 |
Why?
|
| Proportional Hazards Models | 11 | 2022 | 702 | 0.740 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2024 | 380 | 0.730 |
Why?
|
| Radiotherapy | 2 | 2020 | 4 | 0.730 |
Why?
|
| Wine | 3 | 2010 | 18 | 0.730 |
Why?
|
| Quarantine | 1 | 2021 | 10 | 0.710 |
Why?
|
| Electronic Health Records | 7 | 2020 | 707 | 0.700 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 173 | 0.700 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 2 | 0.690 |
Why?
|
| Breast Neoplasms | 6 | 2025 | 977 | 0.680 |
Why?
|
| SEER Program | 6 | 2020 | 94 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 31 | 0.610 |
Why?
|
| Health Status Disparities | 1 | 2020 | 148 | 0.610 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 20 | 0.610 |
Why?
|
| Anti-Retroviral Agents | 4 | 2015 | 82 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 666 | 0.580 |
Why?
|
| Papanicolaou Test | 4 | 2024 | 37 | 0.580 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 120 | 0.580 |
Why?
|
| Comorbidity | 7 | 2023 | 564 | 0.570 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 6 | 0.570 |
Why?
|
| Apoptosis | 2 | 2015 | 11 | 0.570 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 311 | 0.540 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 91 | 0.530 |
Why?
|
| Treatment Outcome | 8 | 2020 | 1170 | 0.510 |
Why?
|
| Fever | 2 | 2014 | 54 | 0.510 |
Why?
|
| Hematinics | 1 | 2016 | 3 | 0.510 |
Why?
|
| Prostatectomy | 2 | 2013 | 75 | 0.510 |
Why?
|
| Erythrocyte Transfusion | 1 | 2016 | 9 | 0.500 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 28 | 0.500 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 5 | 2017 | 32 | 0.490 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 4 | 0.490 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 5 | 0.490 |
Why?
|
| Macrophages | 1 | 2015 | 9 | 0.490 |
Why?
|
| Registries | 7 | 2019 | 460 | 0.490 |
Why?
|
| Health Resources | 1 | 2015 | 34 | 0.480 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 4 | 0.470 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 7 | 0.470 |
Why?
|
| Correspondence as Topic | 1 | 2014 | 4 | 0.460 |
Why?
|
| Health Communication | 1 | 2014 | 16 | 0.460 |
Why?
|
| Smoking | 2 | 2016 | 428 | 0.450 |
Why?
|
| Prostate-Specific Antigen | 4 | 2017 | 76 | 0.440 |
Why?
|
| European Continental Ancestry Group | 6 | 2020 | 480 | 0.430 |
Why?
|
| Product Surveillance, Postmarketing | 5 | 2018 | 96 | 0.420 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 408 | 0.420 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 10 | 0.410 |
Why?
|
| Gammapapillomavirus | 2 | 2010 | 4 | 0.410 |
Why?
|
| Socioeconomic Factors | 6 | 2024 | 609 | 0.410 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1155 | 0.400 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 6 | 0.400 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 25 | 0.400 |
Why?
|
| Autoimmunity | 1 | 2012 | 4 | 0.400 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 538 | 0.390 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 4 | 0.390 |
Why?
|
| Patient Compliance | 1 | 2014 | 278 | 0.390 |
Why?
|
| Palliative Care | 2 | 2023 | 52 | 0.390 |
Why?
|
| Mothers | 2 | 2013 | 103 | 0.390 |
Why?
|
| Hispanic Americans | 5 | 2020 | 378 | 0.390 |
Why?
|
| Viremia | 1 | 2012 | 9 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 51 | 0.380 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 31 | 0.380 |
Why?
|
| Prospective Studies | 6 | 2022 | 1229 | 0.380 |
Why?
|
| Health Promotion | 1 | 2014 | 278 | 0.380 |
Why?
|
| Age Factors | 5 | 2019 | 884 | 0.360 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 1942 | 0.350 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 4 | 0.350 |
Why?
|
| United States | 9 | 2020 | 3891 | 0.350 |
Why?
|
| African Americans | 4 | 2020 | 443 | 0.350 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 1287 | 0.350 |
Why?
|
| Medication Adherence | 2 | 2012 | 239 | 0.340 |
Why?
|
| Patient Preference | 2 | 2025 | 49 | 0.340 |
Why?
|
| Inflammation | 1 | 2010 | 63 | 0.340 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 9 | 0.330 |
Why?
|
| Odds Ratio | 4 | 2017 | 644 | 0.320 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 627 | 0.320 |
Why?
|
| Postmenopause | 1 | 2010 | 248 | 0.320 |
Why?
|
| Herpesviridae Infections | 1 | 2009 | 2 | 0.310 |
Why?
|
| Sarcoma, Kaposi | 1 | 2009 | 12 | 0.310 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 395 | 0.310 |
Why?
|
| Risk Assessment | 5 | 2020 | 1079 | 0.310 |
Why?
|
| Amphetamine | 1 | 2008 | 2 | 0.310 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2008 | 4 | 0.310 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 49 | 0.300 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 31 | 0.290 |
Why?
|
| CD8 Antigens | 1 | 2008 | 2 | 0.290 |
Why?
|
| CD4 Antigens | 1 | 2008 | 2 | 0.290 |
Why?
|
| HIV Seronegativity | 1 | 2008 | 12 | 0.290 |
Why?
|
| Dyslipidemias | 2 | 2020 | 56 | 0.280 |
Why?
|
| Time Factors | 4 | 2020 | 1044 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 316 | 0.270 |
Why?
|
| Liver Diseases | 2 | 2020 | 24 | 0.270 |
Why?
|
| Hypertension | 2 | 2025 | 469 | 0.260 |
Why?
|
| Data Mining | 2 | 2020 | 16 | 0.260 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 45 | 0.260 |
Why?
|
| Chickenpox Vaccine | 3 | 2012 | 91 | 0.260 |
Why?
|
| Anus Neoplasms | 3 | 2017 | 27 | 0.250 |
Why?
|
| Hospitalization | 3 | 2025 | 805 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 124 | 0.250 |
Why?
|
| Trastuzumab | 1 | 2025 | 19 | 0.240 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 9 | 0.240 |
Why?
|
| Alcoholic Beverages | 3 | 2011 | 13 | 0.240 |
Why?
|
| Benzodiazepines | 1 | 2025 | 28 | 0.230 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 31 | 0.230 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2014 | 4 | 0.230 |
Why?
|
| Chronic Disease | 2 | 2020 | 405 | 0.220 |
Why?
|
| Perception | 1 | 2024 | 56 | 0.220 |
Why?
|
| Pneumococcal Infections | 2 | 2016 | 44 | 0.220 |
Why?
|
| Sexual Behavior | 1 | 2025 | 128 | 0.220 |
Why?
|
| Substance-Related Disorders | 2 | 2012 | 424 | 0.220 |
Why?
|
| Pneumococcal Vaccines | 2 | 2016 | 68 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2015 | 6 | 0.220 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 30 | 0.210 |
Why?
|
| Primary Health Care | 1 | 2009 | 729 | 0.210 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 341 | 0.210 |
Why?
|
| Death | 1 | 2023 | 10 | 0.210 |
Why?
|
| Quality of Life | 3 | 2023 | 505 | 0.210 |
Why?
|
| Disease Progression | 2 | 2015 | 259 | 0.210 |
Why?
|
| Biomarkers | 2 | 2017 | 306 | 0.210 |
Why?
|
| Health Behavior | 1 | 2025 | 345 | 0.200 |
Why?
|
| Fertility Preservation | 1 | 2022 | 2 | 0.200 |
Why?
|
| Premature Birth | 1 | 2024 | 132 | 0.190 |
Why?
|
| Myocardial Infarction | 2 | 2015 | 225 | 0.190 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 61 | 0.190 |
Why?
|
| Health Status | 3 | 2025 | 295 | 0.190 |
Why?
|
| Caregivers | 4 | 2023 | 130 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 363 | 0.190 |
Why?
|
| Survival Analysis | 3 | 2020 | 203 | 0.190 |
Why?
|
| Immunization, Secondary | 2 | 2012 | 59 | 0.180 |
Why?
|
| Chickenpox | 2 | 2012 | 35 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 197 | 0.180 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 248 | 0.180 |
Why?
|
| African Continental Ancestry Group | 3 | 2017 | 144 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2013 | 54 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2024 | 805 | 0.180 |
Why?
|
| Logistic Models | 2 | 2016 | 884 | 0.180 |
Why?
|
| Risk | 5 | 2015 | 498 | 0.180 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 21 | 0.180 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 381 | 0.170 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.170 |
Why?
|
| Osteonecrosis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 13 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 285 | 0.170 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 1 | 0.170 |
Why?
|
| Hearing Loss | 1 | 2020 | 18 | 0.170 |
Why?
|
| Medical Overuse | 1 | 2019 | 14 | 0.160 |
Why?
|
| ROC Curve | 2 | 2017 | 73 | 0.160 |
Why?
|
| Cause of Death | 1 | 2020 | 175 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 33 | 0.160 |
Why?
|
| Biopsy | 2 | 2017 | 82 | 0.160 |
Why?
|
| Communication | 2 | 2023 | 181 | 0.160 |
Why?
|
| Child, Preschool | 5 | 2016 | 1375 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2022 | 262 | 0.160 |
Why?
|
| Employment | 1 | 2020 | 44 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 300 | 0.160 |
Why?
|
| Poisson Distribution | 2 | 2016 | 85 | 0.150 |
Why?
|
| Community Health Services | 1 | 2019 | 79 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 180 | 0.150 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 64 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 151 | 0.150 |
Why?
|
| Raltegravir Potassium | 1 | 2018 | 9 | 0.150 |
Why?
|
| Age Distribution | 1 | 2019 | 239 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 201 | 0.150 |
Why?
|
| Heart Failure | 1 | 2024 | 404 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 69 | 0.150 |
Why?
|
| Drug Therapy | 2 | 2020 | 16 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2020 | 154 | 0.140 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2017 | 15 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 311 | 0.140 |
Why?
|
| Data Accuracy | 1 | 2017 | 24 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 22 | 0.140 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.140 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 49 | 0.140 |
Why?
|
| Febrile Neutropenia | 1 | 2017 | 3 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2015 | 109 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1287 | 0.140 |
Why?
|
| Prostate | 2 | 2017 | 28 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 49 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 54 | 0.130 |
Why?
|
| Hospice Care | 1 | 2016 | 9 | 0.130 |
Why?
|
| Infant | 3 | 2016 | 1162 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 184 | 0.130 |
Why?
|
| Data Collection | 2 | 2014 | 240 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2016 | 34 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 56 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 677 | 0.130 |
Why?
|
| Organizational Culture | 1 | 2016 | 15 | 0.130 |
Why?
|
| Leukemia | 1 | 2016 | 9 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 25 | 0.130 |
Why?
|
| Nurses | 1 | 2016 | 34 | 0.130 |
Why?
|
| Ethnic Groups | 3 | 2015 | 456 | 0.120 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 3 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2015 | 7 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 7 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 14 | 0.120 |
Why?
|
| HIV-1 | 2 | 2012 | 71 | 0.120 |
Why?
|
| Research Design | 1 | 2017 | 343 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 455 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2016 | 106 | 0.120 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2015 | 3 | 0.120 |
Why?
|
| Interferon Regulatory Factors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Protein Kinase C beta | 1 | 2015 | 3 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 4 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2016 | 304 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 5 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 8 | 0.120 |
Why?
|
| Coinfection | 1 | 2015 | 31 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 112 | 0.120 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 88 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 67 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 169 | 0.110 |
Why?
|
| Physicians | 1 | 2016 | 128 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2015 | 64 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 44 | 0.110 |
Why?
|
| Premedication | 1 | 2014 | 2 | 0.110 |
Why?
|
| Obesity | 2 | 2022 | 814 | 0.110 |
Why?
|
| Asian Americans | 1 | 2015 | 164 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2019 | 315 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2012 | 280 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 274 | 0.110 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 72 | 0.100 |
Why?
|
| Preventive Medicine | 1 | 2013 | 22 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2013 | 3 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 15 | 0.100 |
Why?
|
| Parents | 1 | 2016 | 287 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 24 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 5 | 0.100 |
Why?
|
| Syncope | 1 | 2012 | 11 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 145 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 102 | 0.100 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 3 | 0.100 |
Why?
|
| B7-1 Antigen | 1 | 2012 | 3 | 0.100 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 6 | 0.100 |
Why?
|
| Minority Groups | 1 | 2013 | 103 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 15 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2012 | 15 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 6 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2012 | 11 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 31 | 0.100 |
Why?
|
| Confidence Intervals | 2 | 2013 | 231 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2012 | 65 | 0.090 |
Why?
|
| Censuses | 1 | 2012 | 29 | 0.090 |
Why?
|
| Vaccines | 1 | 2014 | 218 | 0.090 |
Why?
|
| Stroke | 1 | 2014 | 310 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2012 | 60 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 93 | 0.090 |
Why?
|
| E-Selectin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2010 | 5 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 9 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2010 | 23 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2010 | 25 | 0.090 |
Why?
|
| Patient Selection | 1 | 2012 | 178 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 58 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 107 | 0.080 |
Why?
|
| Washington | 1 | 2011 | 385 | 0.080 |
Why?
|
| Demography | 1 | 2010 | 96 | 0.080 |
Why?
|
| Insulin | 1 | 2010 | 190 | 0.080 |
Why?
|
| Los Angeles | 2 | 2020 | 139 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 342 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 48 | 0.080 |
Why?
|
| Homosexuality | 1 | 2009 | 5 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 140 | 0.080 |
Why?
|
| Herpes Zoster | 1 | 2010 | 82 | 0.070 |
Why?
|
| Genomics | 2 | 2020 | 56 | 0.070 |
Why?
|
| Psoriasis | 1 | 2008 | 9 | 0.070 |
Why?
|
| Beer | 1 | 2007 | 9 | 0.070 |
Why?
|
| North America | 1 | 2007 | 44 | 0.070 |
Why?
|
| Homosexuality, Male | 1 | 2008 | 38 | 0.070 |
Why?
|
| Europe | 1 | 2007 | 46 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 65 | 0.070 |
Why?
|
| Preventive Health Services | 1 | 2009 | 152 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2008 | 103 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 372 | 0.060 |
Why?
|
| Alleles | 2 | 2017 | 80 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2024 | 45 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 7 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2024 | 14 | 0.060 |
Why?
|
| Mortality | 1 | 2024 | 116 | 0.050 |
Why?
|
| Self Report | 1 | 2025 | 257 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2024 | 54 | 0.050 |
Why?
|
| Algorithms | 2 | 2017 | 226 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 367 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 31 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 126 | 0.050 |
Why?
|
| Anthropometry | 1 | 2022 | 60 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2022 | 33 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2022 | 103 | 0.050 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2020 | 6 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 17 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 184 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 937 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 59 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 39 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 23 | 0.030 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 21 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2017 | 87 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 59 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 104 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 16 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 38 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2015 | 52 | 0.030 |
Why?
|
| Pathology | 1 | 2014 | 5 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 839 | 0.030 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 23 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2013 | 5 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 160 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 33 | 0.030 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2012 | 5 | 0.020 |
Why?
|
| Men's Health | 1 | 2012 | 20 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 1466 | 0.020 |
Why?
|
| Graves Disease | 1 | 2012 | 3 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2012 | 6 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2012 | 33 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 51 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 13 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 165 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2012 | 124 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2012 | 75 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 75 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 56 | 0.020 |
Why?
|
| Income | 1 | 2012 | 87 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 179 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 120 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 212 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 165 | 0.020 |
Why?
|
| Virus Activation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2010 | 44 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 253 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 56 | 0.020 |
Why?
|
| Alcoholism | 1 | 2012 | 337 | 0.020 |
Why?
|
| Arthritis, Psoriatic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 27 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 30 | 0.020 |
Why?
|
| Depression | 1 | 2008 | 487 | 0.010 |
Why?
|